Innovation Superheroes

Guest Post : Scott Phillips Editor’s note : I am grateful to Scott for his words as an industry insider. Scott runs a successful and very cool 3D printing business : “The Robots are Coming“. For any kid (and I include myself in that description) who has ever thought that Mum or Dad should have their own superhero figurine, Scott…

No more Alchemistry….

I had a fairly sleepless night last night. It wasn’t just that my 3 year-old woke up at 2am with a night terror, or the periodic squawk across the corridor from the newborn. It wasn’t the ill-advised double-expresso I had after dinner, or even the premonition of a 4am wake-up for a day of business…

ACL : Live and Let Die?

I love a good Bond film and my favorite is, without hesitation, “Live and Let Die”. Charismatic villains, gorgeous but complex “starlets”, and Roger Moore at his gorgonzola-best. McCartney’s awesome sound track is surprisingly glam rock for the era, reminding us that after all the optimism and hope of youth – “live and let live” – is…

Alchemia has a VAST problem

It was only two years ago that Alchemia (ASX : ACL) informed us, with great fanfare and celebration, of the collaboration with AstraZeneca involving the VAST program. It was a pretty exciting story, especially for an early-stage platform technology. R&D cost offsets, potential milestones/royalties. Big potential, heady stuff. Two years on, we have seen the company’s fortunes…

ACL : Erratum (Mr. Ken Poutakidis)

By way of follow-up to my previous post on Alchemia (ASX : ACL), I have been informed that my implied statement that Mr Ken Poutakidis, who recently joined the struggling board of ACL, was previously a director of Phosphagenics (ASX : POH) is in fact incorrect. I made a determination on the basis of reasonable information that was…